Original Research

Published on 26 Apr 2023

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer

in Cancer Immunity and Immunotherapy

Xueyan Liang
Xiaoyu Chen
Huijuan Li
Yan Li

Frontiers in Oncology

doi 10.3389/fonc.2023.1113374

1,835 views

Original Research

Published on 25 Apr 2023

A new prognostic nomogram in patients with mucosa-associated lymphoid tissue lymphoma: a multicenter retrospective study

in Cancer Immunity and Immunotherapy

Qiuyue Wen
Xiaoqian Li
Kewei Zhao
Qiuhui Li
Fang Zhu
Gang Wu
Tongyu Lin
Liling Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1123469

1,634 views
3 citations

Review

Published on 24 Apr 2023

Immunogenic sonodynamic therapy for inducing immunogenic cell death and activating antitumor immunity

in Cancer Immunity and Immunotherapy

Ting Wang
Wangrui Peng
Meng Du
Zhiyi Chen

Frontiers in Oncology

doi 10.3389/fonc.2023.1167105

2,958 views
17 citations

Original Research

Published on 21 Apr 2023

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

in Cancer Immunity and Immunotherapy

Xiaoyong Xiang
Peng Chen
Fengming Lan
Li Ma
Jing Jin
Ye Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1110281

1,617 views
2 citations

Original Research

Published on 20 Apr 2023

High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer

in Cancer Immunity and Immunotherapy

Ibtissam Rezouki
Basma Zohair
Saadia Ait Ssi
Mehdi Karkouri
Ibtissam Razzouki
Mohamed Elkarroumi
Abdallah Badou

Frontiers in Oncology

doi 10.3389/fonc.2023.1154631

2,275 views
8 citations

Original Research

Published on 20 Apr 2023

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study

in Cancer Immunity and Immunotherapy

Shi Tang
Xiaofeng Cong
Dan Zheng
Chen Chen
Zengguang Liu
Jie Gao
Huimin Zhang
Youhao Zhang
Ziling Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1129989

1,958 views
3 citations

Original Research

Published on 19 Apr 2023

Prognostic value of SLC4A4 and its correlation with the microsatellite instability in colorectal cancer

in Cancer Immunity and Immunotherapy

Shaorui Rui
Dong Wang
Yong Huang
Jingyun Xu
Hailang Zhou
Hesong Zhang

Frontiers in Oncology

doi 10.3389/fonc.2023.1179120

2,266 views
4 citations

Review

Published on 19 Apr 2023

UXT at the crossroads of cell death, immunity and neurodegenerative diseases

in Cancer Immunity and Immunotherapy

Pengzhe Han
Shaojian Mo
Zhengwang Wang
Jiale Xu
Xifeng Fu
Yanzhang Tian

Frontiers in Oncology

doi 10.3389/fonc.2023.1179947

3,091 views
3 citations

Systematic Review

Published on 19 Apr 2023

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

in Cancer Immunity and Immunotherapy

Chunlan Chen
Peng Tian
Jiangshan Zhong
Xianming Fan

Frontiers in Oncology

doi 10.3389/fonc.2023.1151769

3,094 views
5 citations

Editorial

Published on 18 Apr 2023

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy

in Cancer Immunity and Immunotherapy

Jieying Yang
Li Fu
Toshiro Shirakawa
Tong Xiang

Frontiers in Oncology

doi 10.3389/fonc.2023.1199811

958 views

Case Report

Published on 18 Apr 2023

The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report

in Cancer Immunity and Immunotherapy

Gangjun Chen
Tian Tian
Xingdong Cai

Frontiers in Oncology

doi 10.3389/fonc.2023.1103512

1,907 views
1 citation

Original Research

Published on 14 Apr 2023

Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study

in Cancer Immunity and Immunotherapy

Shoaib Bashir
Lei Wen
Ping Zhang
Minting Ye
Yin Li
Weiping Hong
Junjie Zhen
Mingyao Lai
Hui Wang
Yanying Yang

Frontiers in Oncology

doi 10.3389/fonc.2023.1068592

1,768 views
2 citations

Systematic Review

Published on 14 Apr 2023

Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials

in Cancer Immunity and Immunotherapy

Chengwei Jin
Jia Qi
Qilei Wang
Chenwei Pu
Mingming Tan

Frontiers in Oncology

doi 10.3389/fonc.2023.1158690

3,787 views
2 citations

Case Report

Published on 14 Apr 2023

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases

in Cancer Immunity and Immunotherapy

Teng Li
Wuyun Hu
Lan Jin
Xianghua Yin
Dongxu Kang
Longzhen Piao

Frontiers in Oncology

doi 10.3389/fonc.2023.1164368

1,931 views
3 citations

Review

Published on 14 Apr 2023

Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review

in Cancer Immunity and Immunotherapy

Yihui Lei
Li Lin
Shuyu Cheng
Qiming Shao
Chenchun Ding
Renjie Zuo
Weiping Chen
Quan Liao
Guoyan Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1072480

1,882 views

Review

Published on 12 Apr 2023

Mutual connected IL-6, EGFR and LIN28/Let7-related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy

in Cancer Immunity and Immunotherapy

Junjun Li
Yazhou Xiao
Huayue Yu
Xia Jin
Songqing Fan
Wei Liu

Frontiers in Oncology

doi 10.3389/fonc.2023.1140133

8,945 views
6 citations

Navigation group

Articles

Cost-effectiveness of cemiplimab plus chemotherapy versus chemotherapy for the treatment of advanced non-small cell lung cancer

A new prognostic nomogram in patients with mucosa-associated lymphoid tissue lymphoma: a multicenter retrospective study

Immunogenic sonodynamic therapy for inducing immunogenic cell death and activating antitumor immunity

The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma

High VISTA expression is linked to a potent epithelial-mesenchymal transition and is positively correlated with PD1 in breast cancer

Concurrent sintilimab with sequential chemoradiotherapy for unresectable, stage III non-small cell lung cancer: a retrospective study

Prognostic value of SLC4A4 and its correlation with the microsatellite instability in colorectal cancer

UXT at the crossroads of cell death, immunity and neurodegenerative diseases

Efficacy and safety of immune checkpoint inhibitors combined with chemotherapy in patients with extensive-stage small cell lung cancer: a systematic review and meta-analysis of randomized controlled trials

Editorial: Targeting tumor vasculature to enhance cancer immunotherapy

The surge of HBsAb level in a HBsAg-negative ES-SCLC patient after anlotinib plus atezolizumab treatment: A case report

Efficacy and safety of combined immunotherapy and stereotactic radiosurgery in NSCLCBM patients and a novel prognostic nomogram: A real-world study

Cardiotoxicity of lung cancer-related immunotherapy versus chemotherapy: a systematic review and network meta-analysis of randomized controlled trials

Case Report: PD-L1-negative advanced bladder cancer effectively treated with anlotinib and tislelizumab: A report of two cases

Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review

Mutual connected IL-6, EGFR and LIN28/Let7-related mechanisms modulate PD-L1 and IGF upregulation in HNSCC using immunotherapy